Cargando…

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma

Background: Tyrosine kinase inhibitors (TKIs) prolong progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC), some of which may achieve long-term responses. Herein, we report clinical and pathological characteristics of patients who achieved long-term responses durin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catalano, Martina, De Giorgi, Ugo, Maruzzo, Marco, Bimbatti, Davide, Buti, Sebastiano, Mazzaschi, Giulia, Procopio, Giuseppe, Santoni, Matteo, Galli, Luca, Conca, Raffaele, Doni, Laura, Antonuzzo, Lorenzo, Roviello, Giandomenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599295/ https://www.ncbi.nlm.nih.gov/pubmed/36289706 http://dx.doi.org/10.3390/biomedicines10102444

Ejemplares similares

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
por: Roviello, Giandomenico, et al.
Publicado: (2022)

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
por: Catalano, Martina, et al.
Publicado: (2020)

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
por: Stellato, Marco, et al.
Publicado: (2021)

Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas
por: Catalano, Martina, et al.
Publicado: (2021)

The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
por: Catalano, Martina, et al.
Publicado: (2022)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study
por: Tommasi, Chiara, et al.
Publicado: (2023)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
por: Catalano, Martina, et al.
Publicado: (2023)

Liquid biopsy in colorectal cancer: No longer young, but not yet old
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Immune combinations and complete response: a new hope for metastatic renal cell carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Editorial: Microbiota and metabolites in cancer immunotherapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis
por: Santini, Daniele, et al.
Publicado: (2017)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
por: Santini, Daniele, et al.
Publicado: (2016)

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review
por: Mazzaschi, Giulia, et al.
Publicado: (2022)

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
por: Maruzzo, Marco, et al.
Publicado: (2021)

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer
por: Roviello, Giandomenico, et al.
Publicado: (2018)

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
por: Procopio, Giuseppe, et al.
Publicado: (2022)

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
por: Rebuzzi, S.E., et al.
Publicado: (2022)

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience
por: Bimbatti, Davide, et al.
Publicado: (2022)

Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
por: Dionese, Michele, et al.
Publicado: (2023)

Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences
por: Santoni, Matteo, et al.
Publicado: (2023)

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
por: Lavacchi, Daniele, et al.
Publicado: (2021)

Therapeutic management of a symptomatic Kaposi’s sarcoma patient with renal failure undergoing haemodialysis: A case report
por: Passarelli, Anna, et al.
Publicado: (2021)

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication
por: Buti, Sebastiano, et al.
Publicado: (2023)

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ic4ivrf7j3254gqhtmuhc1r8i9